Follow The Filings

CRVS Corvus Pharmaceuticals Inc.

Health Care, filed as CORVUS PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.2%
  • $1.2M
  • 1 reduce

In 2026 Q2 David Witzke trimmed Corvus Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 0.2% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke Reduce 0.19%

Who owns CRVS

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 0.19%, was 0.39% Reduce −30.4% 80,000 $1.2M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CRVS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRVS insider trades
  • $334K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. David Scott Moore Director
    Buy
    $250K 21,700 shares at $11.53 New stake
    Traded Jun 11 Filed Jun 15
    ↗
  2. Richard A Miller MD CEO
    Buy
    $83K 6,932 shares at $12.04 +0.6% to stake
    Traded May 18 Filed May 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$27.03M -$62.29M -$15.28M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $27.96M $54.41M $58.21M
Total non-current assets * $17.6M $14.5M $12.9M
Total assets $45.55M $68.91M $71.12M
Total current liabilities $6.87M $35.4M $9.38M
Total non-current liabilities * $0.00 $937,000 $534,000
Total equity $38.68M $32.57M $61.2M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$23.94M -$25.42M -$32.8M
Cash from investing $15.54M -$27.48M -$7.8M
Cash from financing $7.86M $49.03M $36.43M
Net change in cash -$0.539M -$3.88M -$4.16M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf